Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.54 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14791054 | 0.82 | HPGD (0.52) | BAZ2BBAZ2AALDH1A1LMNAGAA | |
| SCHEMBL5173332 | 0.82 | ALPL (0.44) | LMNAGAASMN1; SMN2NPC1ALPL | |
| SCHEMBL31596906 | 0.80 | PARP1 (0.44) | ALDH1A1SMN1; SMN2RAB9ACA1CA2 | |
| SCHEMBL27794126 | 0.79 | BAZ2B (0.58) | BAZ2BBAZ2AALDH1A1LMNAGAA | |
| SCHEMBL21060947 | 0.78 | BAZ2B (0.49) | BAZ2BBAZ2AALDH1A1LMNAGAA | |
| SCHEMBL5202768 | 0.78 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1LMNAGAA | |
| SCHEMBL162449 | 0.78 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1LMNAGAA | |
| SCHEMBL21060866 | 0.78 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1LMNAGAA | |
| SCHEMBL70354 | 0.78 | BAZ2B (0.71) | BAZ2BBAZ2AALDH1A1LMNAGAA | |
| SCHEMBL15764334 | 0.77 | BAZ2B (0.51) | BAZ2BBAZ2AALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | BAZ2B 947/4885BAZ2A 1031/4885ALDH1A1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.